Research programme: neurological disorder therapies - NPS
Alternative Names: CSC 500; CSC 500-204; NPS 156; NPS 1897; NPSP 156Latest Information Update: 24 Feb 2011
At a glance
- Originator NPS Pharmaceuticals
- Class
- Mechanism of Action Glycine gated NMDA receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued CNS disorders; Epilepsy; Neuropathic pain; Schizophrenia
Most Recent Events
- 16 Oct 2007 Preclinical development is ongoing
- 08 Nov 2006 Preclinical trials in Neuropathic pain in USA (unspecified route)
- 31 Oct 2003 Preclinical trials in CNS disorders in USA (unspecified route)